Gathering the record
Relay is organizing the evidence and source boundaries.
Ghrelin-receptor agonist / growth-hormone secretagogue
Ipamorelin activates the ghrelin receptor and can trigger short-term GH release. Human evidence is limited to intravenous studies, and the published Phase 2 postoperative trial did not show significant efficacy. The fat-loss, muscle, sleep, recovery, and anti-aging claims commonly promoted online have not been demonstrated in controlled human trials.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
Ipamorelin is an unapproved experimental compound that can stimulate release of the body's own growth hormone through a ghrelin-related signal.
Researchers investigated its short-term hormone effects and whether it could help bowel function after surgery. The postoperative program tested a clinical outcome beyond hormone measurements, making its result especially informative. That distinction matters here. Online body-composition claims ask much broader questions.
A small intravenous study demonstrated short-term growth-hormone release. A randomized postoperative trial used intravenous ipamorelin but did not improve its key efficacy outcomes.
Controlled evidence does not establish fat loss, muscle gain, recovery, sleep, or anti-aging benefits. How the body responds to subcutaneous administration, repeated-use safety, reconstitution, and product identity also remain unresolved.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
A randomized Phase 2 trial evaluated intravenous ipamorelin after bowel resection; it did not improve the study's primary or secondary efficacy outcomes.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
Human evidence consists mainly of one IV pharmacology study and a negative condition-specific Phase 2 trial.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
IV GH release is demonstrated, but body-composition, sleep, recovery, anti-aging, and SubQ claims are not.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The study used intravenous administration in a postoperative population and cannot validate a subcutaneous bedtime schedule. FDA did not identify route-specific human PK/PD information for proposed subcutaneous administration. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
A randomized 48-person IV pharmacology study demonstrated concentration-dependent GH release, while a 117-person randomized Phase 2 postoperative study did not demonstrate significant efficacy.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Meaningful human benefits, subcutaneous pharmacokinetics and safety, long-term repeated-exposure risk, and effects when combined with another GH-axis compound.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
It targets GHSR1a signaling upstream of pituitary GH release, a different receptor from the GHRH receptor targeted by CJC-1295.
The clearest human pharmacology evidence is an IV dose-escalation study in 48 healthy men.
Ipamorelin did not significantly shorten time to first tolerated meal after bowel resection versus placebo.
Human evidence consists mainly of IV hormone pharmacology and a condition-specific postoperative study that did not show significant efficacy.
The controlled human pharmacology and efficacy studies used intravenous administration.
The compounding votes were separate from drug approval. WADA lists growth-hormone secretagogues under S2.
Mechanisms
Ipamorelin is a synthetic pentapeptide and GHSR1a agonist. Preclinical work describes selective GH-secretagogue activity relative to several other pituitary hormones, but the strongest human pharmacology evidence is a small intravenous dose-escalation study. FDA found no subcutaneous human PK/PD evidence and no adequate effectiveness evidence for growth-hormone deficiency or other promoted uses. A Phase 2 intravenous postoperative-ileus trial did not significantly improve its primary endpoint.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Multicenter, randomized, double-blind, placebo-controlled study after bowel resection
Hospitalized adults after open or laparoscopic small- or large-bowel resection
The primary food-tolerance endpoint was not significantly shorter with ipamorelin, and the study did not demonstrate significant efficacy on key secondary outcomes.
Study administration: Intravenous ipamorelin 0.03 mg/kg twice daily under the study protocol or placebo
Limitations: Single condition-specific Phase 2 study using intravenous dosing. Surgical complications and deaths occurred in the broader safety context; the publication does not establish general outpatient benefit or subcutaneous use.
Randomized, placebo-controlled, intravenous dose-escalation study
Healthy adult men
Ipamorelin produced a concentration-dependent GH response that peaked rapidly and fell to low concentrations by six hours. The estimated terminal half-life was about two hours.
Study administration: Fifteen-minute intravenous ipamorelin infusions across five research-dose groups or placebo
Limitations: Small study in healthy men using intravenous infusion. It measured short-term hormone response, not clinical benefit, and provides no subcutaneous PK/PD evidence.
Randomized, double-blind, placebo-controlled dose-finding study after bowel resection
Adults undergoing small- and/or large-bowel resection
The registry lists the study as completed but does not post results.
Study administration: Intravenous ipamorelin acetate or placebo
Limitations: A completed registration without posted results cannot demonstrate benefit, safety, or a clinically useful dose.
Safety snapshot
No source-qualified adverse-event pattern is represented in the current record.
Evidence boundaryHuman exposure is present, but the record is not detailed enough to characterize a reliable adverse-event pattern.
The current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
No source-qualified compound-specific warning or contraindication is encoded in the current record.
Evidence boundaryNot FDA approved. The 2024 PCAC voted against adding ipamorelin free base or acetate to the 503A Bulks List. Growth-hormone secretagogues are prohibited in sport under WADA S2. Meaningful human benefits, subcutaneous pharmacokinetics and safety, long-term repeated-exposure risk, and effects when combined with another GH-axis compound.
The current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-07-31
2026-01-01
2024-10-29
2024-09-27
2014-10-21 · PMID 25331030 · NCT00672074 · DOI 10.1007/s00384-014-2030-8
2011-01-21 · NCT01280344
1999-09-01 · PMID 10496658 · DOI 10.1023/A:1018955126402